BridgeBio reports positive Phase 3 results for encaleret in ADH1; 76% met primary endpoint

BridgeBio Pharma, Inc.

76% of encaleret-treated patients achieved both serum and urine calcium targets vs 4% on conventional therapy (p<0.0001).
91% on encaleret achieved intact PTH above lower limit vs 7% on conventional therapy (p<0.0001).
Encaleret was well-tolerated with no discontinuations related to study drug.
NDA submission to FDA planned H1 2026; EMA submission to follow.
BridgeBio plans to initiate registrational trials in pediatric ADH1 and chronic hypoparathyroidism in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.